People · Operator
Named in public records as an officer, director or promoter · active 2011–2022 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| DarioHealth Corp. | — | Biotechnology | Series C | $286.5M | $97.8M | 2011 |
| Proxamama, Inc. | — | Other | Series A | $13.5M | $87.8M | 2022 |
Shilo Ben Zeev at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Shilo Ben Zeev on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Anderson | 1 | 10 |
| Richard Stone | 1 | 6 |
| Dennis M McGrath | 1 | 5 |
| Gadi Levin | 1 | 5 |
| Steven Nelson | 1 | 5 |
| Peter Kash | 1 | 4 |
| Adam K Stern | 1 | 4 |
| Malcolm Hoenlein | 1 | 4 |
| Dennis McGrath | 1 | 4 |
| Adam Stern | 1 | 4 |
| Allen Kamer | 1 | 3 |
| Adam D. Stern | 1 | 3 |
| Steven Kaplan | 1 | 3 |
| Chen Franco-Yehuda | 1 | 3 |
| Yalon Farhi | 1 | 2 |
| Hila Karah | 1 | 2 |
| Richard B. Stone | 1 | 2 |
| Nahum Melumad | 1 | 1 |
| Oren Fuerst, Ph.D. | 1 | 1 |
| David Weintraub | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.